New cell therapy trial hopes to tackle recurrent brain cancer
NCT ID NCT06254326
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a personalized cell therapy for adults with recurrent oligodendroglioma, a type of brain tumor. The treatment involves taking a patient's own immune cells and stem cells, modifying them in the lab, and giving them back to fight the tumor. The main goals are to see if this approach is safe and feasible, with only 12 participants planned.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- personalized cell therapy (dendritic cell vaccines, tumor-reactive T cells, and stem cells)
- What this could lead to
- If successful, this could point toward a new treatment option for recurrent oligodendroglioma, a type of brain tumor that is hard to treat.
- What could go wrong
- This is a very early Phase 1 trial with only 12 participants, so it is primarily testing safety and feasibility. The treatment is complex and may cause severe side effects, and it is not yet known if it will help control the tumor.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROGRESSIVE OLIGODENDROGLIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Florida Health Shands Hospital
RECRUITINGGainesville, Florida, 32610, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.